skip to primary navigationskip to content
 

19.12.18 Potential for new eye drop medicine to help Acute Myeloid Leukemia

last modified Dec 21, 2018 03:10 PM
A new study in Nature Communications describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML.
19.12.18 Potential for new eye drop medicine to help Acute Myeloid Leukemia

Overlap of genes with splicing changes after genetic or pharmacological inhibition of SRPK1

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4

Tzelepis K et al. (2018) Nature Communications 9: 5378.

DOI: 10.1038/s41467-018-07620-0

 

Press release from the Sanger Institute

An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists at the Wellcome Sanger Institute, University of Cambridge's Gurdon Institute, University of Nottingham and their collaborators have found that this compound, which targets an essential cancer gene, could kill leukaemia cells without harming non-leukemic blood cells. 

The results, published today (19 December) in Nature Communications reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis. 

Acute myeloid leukaemia (AML) is a form of blood cancer that affects people of all ages, often requiring months of intensive chemotherapy and prolonged hospital admissions. It develops in cells in the bone marrow crowding out the healthy cells, in turn leading to life-threatening infections and bleeding. 

Mainstream AML treatments have remained unchanged for over thirty years, with the current treatment being chemotherapy, and the majority of people's cancer cannot be cured. A subtype of AML, driven by rearrangements in the MLL gene has a particularly bad prognosis.

In a previous study, researchers at the Sanger Institute developed an approach, based on CRISPR gene editing technology, which helped them identify more than 400 genes as possible therapeutic targets for different subtypes of AML. One of the genes, SRPK1, was found to be essential for the growth of MLL-rearranged AML. SRPK1 is involved in a process called RNA splicing, which prepares RNA for translation into proteins, the molecules that conduct the majority of normal cellular processes, including growth and proliferation.

In a new study, Sanger Institute researchers and their collaborators set out to work out how inhibition of SRPK1 can kill AML cells and whether it has therapeutic potential in this disease. They first showed that genetic disruption of SRPK1 stopped the growth of MLL-rearranged AML cells and then went on to study the compound SPHINX31, an inhibitor of SRPK1, which was being used to develop an eye drop treatment for retinal neovascular disease - the growth of new blood vessels on the retinal surface that bleed spontaneously and cause vision loss.

The team found that the compound strongly inhibited the growth of several MLL-rearranged AML cell lines, but did not inhibit the growth of normal blood stem cells. They then transplanted patient-derived human AML cells into immunocompromised mice and treated them with the compound. Strikingly, the growth of AML cells was strongly inhibited and the mice did not show any noticeable side effects. 

Dr George Vassiliou, joint leader of the research from the Wellcome Sanger Institute and the Wellcome-MRC Cambridge Stem Cell Institute, said: "We have discovered that inhibiting a key gene with a compound being developed for an eye condition can stop the growth of an aggressive form of acute myeloid leukaemia without harming healthy cells. This shows promise as a potential approach for treating this aggressive leukaemia in humans." 

SRPK1 controls the splicing* of RNA in the production of new proteins. An example of a gene that is affected when SRPK1 is blocked is BRD4, a well-known gene that maintains AML. Inhibiting SRPK1 causes the main form of BRD4 to switch to another form, a change that is detrimental to AML growth. 

Dr Konstantinos Tzelepis, joint lead author from the Wellcome Sanger Institute and the Wellcome Trust Cancer Research UK Gurdon Institute, University of Cambridge, said: "Our study describes a novel mechanism required for leukaemia cell survival and highlights the therapeutic potential of SRPK1 inhibition in an aggressive type of AML. Targeting this mechanism may be effective in other cancers where BRD4 and SRPK1 play a role, such as metastatic breast cancer."

Professor David Bates, from the University of Nottingham and co-founder of biotech company Exonate, which develops eye drops for retinal diseases, said: "When Dr Vassiliou told me that SRPK1 was required for the survival of a form of AML, I immediately wanted to work with him to find out if our inhibitors could actually stop the leukaemia cells growing. The fact that the compound worked so effectively bodes well for its potential development as a new therapy for leukaemia. It will take some time, but there is real promise for a new treatment on the horizon for patients with this aggressive cancer."

(This release was posted on Eurekalert).

++++++++++++++++++

 

Read more about research in the Kouzarides lab.

Watch Tony Kouzarides describe his research on video.

Studying development to understand disease

The Gurdon Institute is funded by Wellcome and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.

combinedLogo x3 trans2018

 

Share this

Liver organoids: from basic research to therapeutic applications

NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs

The roles of DNA, RNA and histone methylation in ageing and cancer

Separating Golgi proteins from cis to trans reveals underlying properties of cisternal localization

Sequencing cell-type-specific transcriptomes with SLAM-ITseq

Mature sperm small-RNA profile in the sparrow: implications for transgenerational effects of age on fitness

Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction

Derivation and maintenance of mouse haploid embryonic stem cells

Establishment of porcine and human expanded potential stem cells

Adapting machine-learning algorithms to design gene circuits

Lgr5+ stem/progenitor cells reside at the apex of a heterogeneous embryonic hepatoblast pool

Identification of a regeneration-organizing cell in the Xenopus tail

Citrullination of HP1γ chromodomain affects association with chromatin

A critical but divergent role of PRDM14 in human primordial germ cell fate revealed by inducible degrons

A transmissible RNA pathway in honey bees

METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation

A Secreted RNA Binding Protein Forms RNA-Stabilizing Granules in the Honeybee Royal Jelly

The Human Lung Cell Atlas - A high-resolution reference map of the human lung in health and disease

A Compendium of Mutational Signatures of Environmental Agents

Characteristics and homogeneity of N6-methylation in human genomes

Link to full list on PubMed